spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  vernakalant 

 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA to Acquire Correvio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jun 2019
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 29 Nov 2017
Aethlon Medical Names Dr. Charles J. Fisher Chairman of the Board
Devices Personnel
 HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 21 Aug 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch
 HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 26 Sep 2012
Merck Returns Global Marketing and Development Rights for Vernakalant to Cardiome
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Sep 2012
Cardiome Announces Appointment of Jennifer Archibald as Chief Financial Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 25 Jun 2010
Investigational BRINAVESS (vernakalant) for Infusion Recommended for Approval by the CHMP in the European Union (EU) for the Rapid Conversion of Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 14 May 2010
Merck and Cardiome Announce Phase III Study Results Comparing Investigational Compound BRINAVESS(TM) (Vernakalant) Intravenous to Amiodarone Injection in Conversion of Atrial Fibrillation to Normal Sinus Rhythm
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2009
Marketing Application for Vernakalant Intravenous (IV) Filed in Europe for the Treatment of Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 19 May 2009
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 11 Aug 2008
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 25 Mar 2008
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Jan 2008
Cardiome And Astellas Announce Regulatory Update
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2007
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 7 Nov 2007
Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Oct 2007
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Apr 2007
Cardiome Announces In-Licensing Agreement With Eli Lilly and Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Mar 2007
Cardiome Announces Appointment of Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2007
Cardiome Announces Management Appointments
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 27 Sep 2006
Cardiome Announces USAN Name And Patent Grant
Biopharmaceuticals Cardiology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.